TaiMed Biologics Inc (中裕新藥) plans to apply within a month to the US Food and Drug Administration (FDA) for permission to license its Trogarzo “by intravenous push” treatment, as the company’s phase 3 clinical trial showed promising results, it said in a filing with the Taipei Exchange on Sunday.
On March 1, 2019, the HIV/AIDS drug developer began its last stage of human testing in the US to observe whether Trogarzo by intravenous push could produce the same effect as its Trogarzo “by intravenous infusion” treatment, which has already been launched.
Trogarzo by intravenous infusion needs to be diluted with saline solution and administration of the medication takes 15 minutes, while Trogarzo by intravenous push can be given to patients undiluted and takes only 30 seconds to administer, the company said.
Twenty-two people who were infected with HIV-1, but were in a stable condition and had already taken Trogarzo by intravenous infusion for at least three months, participated in the phase 3 trial, TaiMed said in the filing.
Participants initially took Trogarzo by intravenous infusion once every two weeks, but later took Trogarzo by intravenous push, also once every two weeks, the company said.
They did not report any severe adverse reactions, but some had mild or medium adverse reactions, it said.
The concentration of Trogarzo declined at similar rates in participants treated using the intravenous infusion and intravenous push methods, indicating that the different administration routes did not affect the rate of the drugs’ absorption, TaiMed said.
The different methods of administration did not lead to a change in participants’ viral loads, and no one reported viral loads of more than than 1,000 copies per milliliter twice consecutively, it said.
Meanwhile, no participants developed anti-Trogarzo antibodies, TaiMed said.
“Overall, the test results have reached our objectives. We will apply for a biologics license,” TaiMed said. “It is expected that we will obtain approval within a few months.”
TaiMed paid about US$2 million for the phase 3 clinical trail, which was carried out by a contract research organization, it said, adding that the payment excluded drug expenses and research costs.
The company said it expects to receive a milestone payment of US$3 million from its marketing and distribution partner, Theratechnologies Inc, if it gains approval from the FDA.
TaiMed has signed a 12-year contract with Theratechnologies, which would be in charge of sales of Trogarzo by intravenous push in the US, Canada, most European countries and Israel.
It has signed another contract with Meroven Ltd, which would market the medication in the Middle East and North Africa.
Among the rows of vibrators, rubber torsos and leather harnesses at a Chinese sex toys exhibition in Shanghai this weekend, the beginnings of an artificial intelligence (AI)-driven shift in the industry quietly pulsed. China manufactures about 70 percent of the world’s sex toys, most of it the “hardware” on display at the fair — whether that be technicolor tentacled dildos or hyper-realistic personalized silicone dolls. Yet smart toys have been rising in popularity for some time. Many major European and US brands already offer tech-enhanced products that can enable long-distance love, monitor well-being and even bring people one step closer to
Malaysia’s leader yesterday announced plans to build a massive semiconductor design park, aiming to boost the Southeast Asian nation’s role in the global chip industry. A prominent player in the semiconductor industry for decades, Malaysia accounts for an estimated 13 percent of global back-end manufacturing, according to German tech giant Bosch. Now it wants to go beyond production and emerge as a chip design powerhouse too, Malaysian Prime Minister Anwar Ibrahim said. “I am pleased to announce the largest IC (integrated circuit) Design Park in Southeast Asia, that will house world-class anchor tenants and collaborate with global companies such as Arm [Holdings PLC],”
Sales in the retail, and food and beverage sectors last month continued to rise, increasing 0.7 percent and 13.6 percent respectively from a year earlier, setting record highs for the month of March, the Ministry of Economic Affairs said yesterday. Sales in the wholesale sector also grew last month by 4.6 annually, mainly due to the business opportunities for emerging applications related to artificial intelligence (AI) and high-performance computing technologies, the ministry said in a report. The ministry forecast that retail, and food and beverage sales this month would retain their growth momentum as the former would benefit from Tomb Sweeping Day
Thousands of parents in Singapore are furious after a Cordlife Group Ltd (康盛人生集團), a major operator of cord blood banks in Asia, irreparably damaged their children’s samples through improper handling, with some now pursuing legal action. The ongoing case, one of the worst to hit the largely untested industry, has renewed concerns over companies marketing themselves to anxious parents with mostly unproven assurances. This has implications across the region, given Cordlife’s operations in Hong Kong, Macau, Indonesia, the Philippines and India. The parents paid for years to have their infants’ cord blood stored, with the understanding that the stem cells they contained